{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:06:59Z","timestamp":1788217619436,"version":"build-2803163510"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Legresley Family Foundation"},{"name":"Princess Margaret Cancer Foundation"},{"name":"The Terry Fox Research Institute (TFRI) Marathon of Hope Cancer Centres Network (MOHCCN)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Comprehensive molecular profiling can identify alterations in biliary tract cancer (BTC) potentially treatable with targeted therapies. However, the impact of whole-genome and transcriptome sequencing (WGTS) on therapeutic decision-making in a public healthcare system is unknown. Here, BTC patients prospectively received WGTS to inform clinical care at a large Canadian academic cancer center. We characterized the proportion of targetable alterations, the treatment recommendations generated by a molecular tumor board, targeted therapies received, patient outcomes, and the financing of these treatments. A total of 55 patients with BTC prospectively underwent WGTS to inform clinical care. Of those 55, 28 (51%, 95% CI 38\u201364%) harbored targetable alterations. Molecular tumor boards recommended consideration of targeted therapies for 43 (78% CI: 66\u201387%) of 55 cases. Among the 15 patients who progressed to second-line therapy and harbored targetable alterations, 8 received nine targeted therapies. No targeted therapies were funded through the public system, and most therapies were funded through compassionate access programs from companies. These results highlight the challenges and potential for inequities when implementing precision oncology in a publicly funded healthcare system.<\/jats:p>","DOI":"10.3390\/curroncol32020080","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T04:05:47Z","timestamp":1738296347000},"page":"80","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System"],"prefix":"10.3390","volume":"32","author":[{"given":"Felix E. G.","family":"Beaudry","sequence":"first","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada"},{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5654-7043","authenticated-orcid":false,"given":"Zhihao","family":"Li","sequence":"additional","affiliation":[{"name":"Toronto General Hospital, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8058-8953","authenticated-orcid":false,"given":"Ayelet","family":"Borgida","sequence":"additional","affiliation":[{"name":"Toronto General Hospital, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anudari","family":"Zorigtbaatar","sequence":"additional","affiliation":[{"name":"Toronto General Hospital, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Surgery, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6292-3087","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Eliot Phillipson Clinician-Scientist Training Program, University of Toronto, Toronto, ON M5S 3H2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Hildebrand","sequence":"additional","affiliation":[{"name":"Toronto General Hospital, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumaima","family":"Hamza","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun Ho","family":"Jang","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Bucur","sequence":"additional","affiliation":[{"name":"Toronto General Hospital, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0649-0760","authenticated-orcid":false,"given":"Anna","family":"Dodd","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-962X","authenticated-orcid":false,"given":"Julie","family":"Wilson","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Auer","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, ON K1Y 1J8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Saibil","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica S.","family":"Tsang","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Toronto General Hospital, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grainne M.","family":"O\u2019Kane","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s University Hospital, School of Medicine, University College Dublin, Dublin D04 T6F4, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gallinger","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada"},{"name":"Department of Surgery, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada"},{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiyaz","family":"Notta","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada"},{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Sapisochin","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Toronto General Hospital, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Surgery, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Grant","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada"},{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, ON M5G 2C4, Canada"},{"name":"Institute for Clinical Evaluative Sciences, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int."},{"key":"ref_3","first-page":"EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM \u00c9vid."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1245\/s10434-019-07175-4","article-title":"Intrahepatic Cholangiocarcinoma: Socioeconomic Discrepancies, Contemporary Treatment Approaches and Survival Trends from the National Cancer Database","volume":"26","author":"Uhlig","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.3390\/curroncol30080517","article-title":"A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada","volume":"30","author":"Ramjeesingh","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102049","DOI":"10.1016\/j.esmoop.2023.102049","article-title":"Futibatinib: Second EMA approval for FGFR inhibitor in cholangiocarcinoma","volume":"8","author":"Lamarca","year":"2023","journal-title":"ESMO Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Kim","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: Fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat. Methods"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1101\/gr.221028.117","article-title":"SvABA: Genome-wide detection of structural variants and indels by local assembly","volume":"28","author":"Wala","year":"2018","journal-title":"Genome Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","article-title":"Manta: Rapid detection of structural variants and indels for germline and cancer sequencing applications","volume":"32","author":"Chen","year":"2016","journal-title":"Bioinformatics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","article-title":"DELLY: Structural variant discovery by integrated paired-end and split-read analysis","volume":"28","author":"Rausch","year":"2012","journal-title":"Bioinformatics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature19823","article-title":"A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns","volume":"538","author":"Notta","year":"2016","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1053\/j.gastro.2021.01.220","article-title":"Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma","volume":"160","author":"Golan","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cancergen.2023.08.025","article-title":"Djerba: A modular system to generate clinical genome interpretation reports for cancer","volume":"278","author":"Bancarz","year":"2023","journal-title":"Cancer Genet."},{"key":"ref_23","first-page":"18","article-title":"Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology","volume":"11","author":"Chen","year":"2024","journal-title":"J. Cancer Res. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","article-title":"Molecular Tumor Boards in Clinical Practice","volume":"6","author":"Luchini","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: First-Line Pemigatinib vs Gemcitabine plus Cisplatin for Advanced Cholangiocarcinoma with FGFR2 Rearrangements","volume":"16","author":"Valle","year":"2020","journal-title":"Future Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"JCO"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and Trastuzumab for HER2-Positive, Metastatic Biliary Tract Cancer (MyPathway): A Multicentre, Open-Label, Phase 2a, Multiple Basket Study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2\u2013Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial","volume":"42","author":"Ohba","year":"2024","journal-title":"JCO"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus Trametinib in BRAFV600E-Mutated Rare Cancers: The Phase 2 ROAR Trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rose, A.A.N., Maxwell, J., Rousselle, E., Riaud, M., Tobin, C., Mcguire, M., King, I., Zhang, T., Saeed Kamil, Z., and Pugh, T.J. (2024). Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors with Non-V600E BRAF Mutations (Mts): Final Results of the Investigator-Initiated Phase II BEAVER Trial. JCO, 42.","DOI":"10.1200\/JCO.2024.42.16_suppl.3104"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Macarulla, T., Yamamoto, N., Tolcher, A.W., Hafez, N., Lugowska, I., Ramlau, R., Geng, J., Li, J., Teufel, M., and Maerten, A. (2024). Efficacy and Safety of Brigimadlin (BI 907828), an MDM2\u2013P53 Antagonist, in Patients (Pts) with Advanced Biliary Tract Cancer: Data from Two Phase Ia\/Ib Dose-Escalation\/Expansion Trials. JCO, 42.","DOI":"10.1200\/JCO.2024.42.3_suppl.487"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pant, S., Yaeger, R., Spira, A.I., Pelster, M., Sabari, J.K., Hafez, N., Barve, M.A., Velastegui, K., Yan, X., and Der-Torossian, H. (2023). KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Advanced Solid Tumors Harboring a KRASG12C Mutation. JCO, 41.","DOI":"10.1200\/JCO.2023.41.36_suppl.425082"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S484","DOI":"10.1016\/j.annonc.2024.08.671","article-title":"604O Phase I Dose Escalation and Initial Dose Expansion Results of AMG 193: A MTA-Cooperative PRMT5 Inhibitor, in Patients (Pts) with MTAP-Deleted Solid Tumors","volume":"35","author":"Sacher","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(24)00286-9","article-title":"Clinical Benefit, Reimbursement Outcomes, and Prices of FDA-Approved Cancer Drugs Reviewed through Project Orbis in the USA, Canada, England, and Scotland: A Retrospective, Comparative Analysis","volume":"25","author":"Jenei","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102443","DOI":"10.1016\/j.eclinm.2024.102443","article-title":"Impact on Costs and Outcomes of Multi-Gene Panel Testing for Advanced Solid Malignancies: A Cost-Consequence Analysis Using Linked Administrative Data","volume":"69","author":"Nguyen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e2200546","DOI":"10.1200\/PO.22.00546","article-title":"Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non\u2013Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers","volume":"7","author":"Arriola","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jval.2024.04.023","article-title":"Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review","volume":"27","author":"Mirza","year":"2024","journal-title":"Value Health"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","article-title":"Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced\/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States","volume":"24","author":"Zou","year":"2022","journal-title":"J. Mol. Diagn."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3892\/mco.2021.2453","article-title":"Cost-Effectiveness of Precision Cancer Medicine-Current Challenges in the Use of next Generation Sequencing for Comprehensive Tumour Genomic Profiling and the Role of Clinical Utility Frameworks (Review)","volume":"16","author":"Christofyllakis","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"ref_43","unstructured":"(2025, January 22). pemigatinib | CDA-AMC. Available online: https:\/\/www.cda-amc.ca\/pemigatinib."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40273-022-01227-6","article-title":"Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy","volume":"41","author":"Chueh","year":"2023","journal-title":"PharmacoEconomics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12962-023-00473-5","article-title":"Cost-Effectiveness of Pemigatinib as a Second-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions in Taiwan: From the Evidence of the Phase II Trial and the Perspective of Taiwan\u2019s National Health Insurance Administration","volume":"21","author":"Chen","year":"2023","journal-title":"Cost Eff. Resour. Alloc."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Chen, K.-A., Huang, W.-M., Chen, E.Y.-T., Ho, P.-K., Chueh, C.-H., Wen, Y.-W., Chen, M.-H., Chiang, N.-J., and Tsai, Y.-W. (2024). Cost-Effectiveness of Ivosidenib versus Chemotherapy for Previously Treated IDH1-Mutant Advanced Intrahepatic Cholangiocarcinoma in Taiwan. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12362-y"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Love, T.M., Anaya, D.A., Prime, M.S., Ardolino, L., and Ekinci, O. (2022). Development and Validation of ACTE-MTB: A Tool to Systematically Assess the Maturity of Molecular Tumor Boards. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0268477"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/80\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:24:35Z","timestamp":1760027075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/80"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["curroncol32020080"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32020080","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}